Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arcus Biosciences Q4 2023 GAAP EPS $(1.08) Misses $(0.98) Estimate, Sales $31.00M Beat $28.37M Estimate

Author: Benzinga Newsdesk | February 21, 2024 05:28pm
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.98) by 10.2 percent. This is a 16.13 percent decrease over losses of $(0.93) per share from the same period last year. The company reported quarterly sales of $31.00 million which beat the analyst consensus estimate of $28.37 million by 9.28 percent. This is a 8.82 percent decrease over sales of $34.00 million the same period last year.

Posted In: RCUS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist